TuisI9DN • FRA
add
Arbutus Biopharma Corp
Vorige sluiting
€2,75
Dagwisseling
€2,72 - €2,72
Jaarwisseling
€2,52 - €4,22
Markkapitalisasie
589,90 m USD
Gemiddelde volume
275,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Investing.com
2 dae gelede
Arbutus Biopharma earnings missed by $0.03, revenue fell short of estimates
1,28%
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,76 m | 15,14% |
Bedryfskoste | 5,83 m | 9,79% |
Netto inkomste | -24,53 m | -37,21% |
Netto winsgrens | -1,39 k | -19,16% |
Wins per aandeel | -0,18 | -32,01% |
EBITDA | -12,68 m | 32,64% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 112,71 m | -12,79% |
Totale bates | 117,01 m | -22,14% |
Totale aanspreeklikheid | 37,85 m | 6,17% |
Totale ekwiteit | 79,16 m | — |
Uitstaande aandele | 191,50 m | — |
Prys om te bespreek | 6,71 | — |
Opbrengs op bates | -26,19% | — |
Opbrengs op kapitaal | -34,60% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -24,53 m | -37,21% |
Kontant van bedrywe | -13,39 m | 30,60% |
Kontant van beleggings | 11,35 m | -2,95% |
Kontant van finansiering | 2,78 m | -88,60% |
Netto kontantverandering | 746,00 k | -95,56% |
Beskikbare kontantvloei | -3,83 m | 69,61% |
Meer oor
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Gestig
2007
Webwerf
Werknemers
44
